UPCOMING SESSIONS in ET
Fri, Nov 20, 2026
6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness Hamide Eygoren Register
UPCOMING SESSIONS in ET
Fri, Nov 20, 2026 · 6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness
Hamide Eygoren
Register
View all sessions

Amyloidosis Therapeutics Market to Reach USD 6.3 Billion by 2035, Driven by Targeted Treatment Innovations

Key Information
summary/abstract

The amyloidosis therapeutics market is experiencing notable growth, with its valuation estimated at USD 2.7 billion in 2024 and projected to reach approximately USD 6.3 billion by 2035, expanding at a steady CAGR of around 8.2% during the forecast period. This growth is primarily driven by increasing prevalence of amyloidosis, particularly transthyretin-related cases, along with advancements in early diagnostic techniques and the rising adoption of targeted therapies such as gene-silencing drugs and monoclonal antibodies.

The amyloidosis therapeutics market is witnessing steady growth as healthcare systems across the globe focus more on rare and complex diseases. Amyloidosis refers to a group of disorders caused by the abnormal deposition of misfolded proteins, known as amyloid fibrils, in various organs such as the heart, kidneys, liver, and nervous system. These deposits disrupt normal organ function and can lead to life-threatening complications if left untreated.